Tech Company Financing Transactions
Vor Biopharma Funding Round
On 7/8/2020, Vor Biopharma landed $110 million in Series B funding from RA Capital, 5AM Ventures and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
7/8/2020
Transaction Type
Venture Equity
Amount
$110,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds will advance the company's lead candidate VOR33 into clinical trials, deepen its portfolio, and accelerate the validation of additional targets for its scientific platform, which is designed to remove redundant proteins so that transplanted stem cells become invisible to targeted therapies while leaving diseased cells vulnerable.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
215 1st St. 430
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Vor Biopharma is an immuno-oncology company developing novel therapies with broad potential for treating cancer. Vor is focused on developing technologies that can enable selective targeting of cancer cells without impacting normal cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Siddhartha Mukherjee
Chief Executive Officer
Robert Ang
Chief Financial Officer
Nathan Jorgensen
Chief Medical Officer
Christopher Slapak
Chief Technical Officer
Sadik Kassim
VP - General Counsel
Amy Mendel
VP - Human Resources
Tania Philipp
VP - R & D
Tirtha Chakraborty
VP - Regulatory Affairs
Robert Pietrusko
Browse more venture capital transactions:
Prev: 7/8/2020: Vital4 venture capital transaction
Next: 7/8/2020: Sayari Labs venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs